The development of anti-EGFR resistance is a complex process that involves multiple genes and factors due to the heterogeneity of tumour tissues.Kras is a frequently mutated oncogene in CRC, with a mutation frequency of approximately 40%, and up to 95% of mutations occur in exons G12 and G13[5]. This evidence concerns the gene EGFR and colorectal carcinoma.